Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposome bupivacaine (Pacira BioSciences, 045be0)
- Development stage
- Unknown
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
Liposome bupivacaine is an extended-release formulation of the amide-type local anesthetic bupivacaine, utilizing the DepoFoam multivesicular liposome technology. It is designed to provide prolonged postsurgical analgesia by slowly releasing bupivacaine into the surgical site over several days. Developed by Pacira BioSciences, it is primarily indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block. By blocking voltage-gated sodium channels on the internal surface of nerve cell membranes, it prevents the generation and conduction of nerve impulses, thereby providing pain relief.
- Brand names
- Exparel
- Other names
- bupivacaine liposomeliposomal bupivacainebupivacaine liposome injectable suspension
02
Targets
KCNK2 (Potassium channel subfamily K member 2)KCNK9 (Potassium channel subfamily K member 9)SCN5A (Sodium channel protein type 5 subunit alpha)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on liposome bupivacaine (Pacira BioSciences, 045be0).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposome bupivacaine (Pacira BioSciences, 045be0).